Commerzbank Analysts Give Fresenius Medical Care AG & Co. KGaA (FME) a €79.00 Price Target

Fresenius Medical Care AG & Co. KGaA (ETR:FME) has been given a €79.00 ($91.86) target price by investment analysts at Commerzbank in a report issued on Friday. The firm presently has a “neutral” rating on the stock. Commerzbank’s price objective would suggest a potential upside of 23.86% from the company’s current price.

Other equities research analysts have also recently issued reports about the company. Goldman Sachs Group set a €98.00 ($113.95) price target on Fresenius Medical Care AG & Co. KGaA and gave the company a “buy” rating in a research report on Monday, October 1st. UBS Group set a €86.00 ($100.00) price target on Fresenius Medical Care AG & Co. KGaA and gave the company a “neutral” rating in a research report on Wednesday, October 17th. JPMorgan Chase & Co. set a €84.20 ($97.91) price target on Fresenius Medical Care AG & Co. KGaA and gave the company a “buy” rating in a research report on Friday. Nord/LB set a €85.00 ($98.84) price target on Fresenius Medical Care AG & Co. KGaA and gave the company a “buy” rating in a research report on Wednesday, October 17th. Finally, Barclays set a €87.20 ($101.40) price target on Fresenius Medical Care AG & Co. KGaA and gave the company a “neutral” rating in a research report on Wednesday, October 17th. Nine equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of €87.91 ($102.22).

ETR FME opened at €63.78 ($74.16) on Friday. Fresenius Medical Care AG & Co. KGaA has a 52 week low of €75.53 ($87.83) and a 52 week high of €93.82 ($109.09).

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the U.S.

Featured Story: SEC Filing

Analyst Recommendations for Fresenius Medical Care AG & Co. KGaA (ETR:FME)

Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply